Shattuck Labs Inc. (STTK)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Investors who lost money on Shattuck Labs, Inc. should contact Levi & Korsinsky about an ongoing investigation - STTK
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Announces an Investigation on Behalf of Shattuck Labs, Inc. (STTK) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Shareholders that Lost Money on Shattuck Labs, Inc. (STTK) Should Contact Levi & Korsinsky About Securities Fraud Investigation - STTK
NEW YORK, NY / ACCESSWIRE / October 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/STTK.
Shattuck Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Shattuck Labs, Inc. (STTK)
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
STTK STOCK ALERT: Levi & Korsinsky Notifies Shattuck Labs, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Shattuck Labs, Inc. ("Shattuck Labs, Inc.") (NASDAQ:STTK) concerning possible violations of federal securities laws. On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.
